Related Experiment Videos
[Pefloxacin in the treatment of recurrent urinary tract infections]
A Oksa1, V Dzúriková, M Gajdos
1Centrum klinickej farmakológie Výskumného ústavu lekárskej bioniky, Bratislava.
Abstract:
Thirty-seven patients with relapsing infections of the urinary tract were treated with pefloxacine, 400 mg/12 h for a period of 7-28 days. The clinical success of treatment was 100%, the bacteriological success 95%. Within 3-4 weeks after termination of treatment 63% of the patients did not develop a relapse, in particular those who did not have morphological changes of the kidneys. Side-effects-gastrointestinal, nervous, dermatological--during treatment were not severe. The results are comparable with results of the effect of ofloxacine in a similar group of patients.
Insights
Pefloxacin effectively treated relapsing urinary tract infections in 37 patients, achieving 100% clinical and 95% bacteriological success. Most patients remained relapse-free post-treatment, with mild side effects observed.
Area of Science:
- Infectious Diseases
- Pharmacology
- Urology
Background:
- Recurrent urinary tract infections (UTIs) pose a significant clinical challenge.
- Effective antibiotic therapies are crucial for managing relapsing UTIs.
- Pefloxacin is a fluoroquinolone antibiotic with broad-spectrum activity.
Purpose of the Study:
- To evaluate the efficacy and safety of pefloxacin in treating patients with relapsing urinary tract infections.
- To assess the relapse rates after pefloxacin treatment for recurrent UTIs.
Main Methods:
- A cohort of 37 patients with relapsing UTIs received pefloxacin 400 mg every 12 hours.
- Treatment duration ranged from 7 to 28 days.
- Clinical and bacteriological outcomes, relapse rates, and side effects were monitored.
Main Results:
- 100% clinical success and 95% bacteriological success were achieved with pefloxacin treatment.
- Within 3-4 weeks post-treatment, 63% of patients remained relapse-free.
- Patients without kidney morphological changes showed lower relapse rates.
- Reported side effects (gastrointestinal, nervous, dermatological) were not severe.
Conclusions:
- Pefloxacin demonstrates high efficacy in treating relapsing urinary tract infections.
- The drug is well-tolerated, with a favorable safety profile.
- Pefloxacin offers a comparable treatment option to ofloxacin for recurrent UTIs.